Management of Elevated Blood Sugar with Insulin
For hospitalized patients with elevated blood glucose ≥180 mg/dL, initiate insulin therapy using a basal-bolus regimen (0.3-0.5 U/kg/day total, split 50% basal and 50% prandial) for type 2 diabetes, while critically ill patients should receive continuous intravenous insulin infusion targeting 140-180 mg/dL. 1, 2
Critical Care Setting
In critically ill patients, start IV insulin infusion when blood glucose exceeds 180 mg/dL and maintain levels between 140-180 mg/dL 1, 3. Avoid targeting euglycemia (80-110 mg/dL) as this substantially increases hypoglycemia risk without mortality benefit 1. Continuous IV insulin is the gold standard for this population because it allows rapid dose adjustments matching the dynamic metabolic changes in critical illness 4, 5.
Non-Critical Care Hospitalized Patients
For Type 2 Diabetes Patients
Use basal-bolus insulin regimen, NOT sliding scale insulin alone 1. This approach consistently demonstrates superior glycemic control and reduces complications including wound infections, pneumonia, bacteremia, and renal/respiratory failure 1.
Dosing algorithm:
- Insulin-naive or low-dose patients: Start 0.3-0.5 U/kg/day total daily dose
- 50% as basal insulin (once or twice daily)
- 50% as rapid-acting insulin (divided before three meals)
- Patients on home insulin ≥0.6 U/kg/day: Reduce total dose by 20% to prevent hypoglycemia from decreased oral intake 1
- High-risk patients (age >65, renal failure, poor oral intake): Use lower end of dosing range 1
For Type 1 Diabetes Patients
Never use sliding scale insulin alone - this is a critical pitfall that can lead to diabetic ketoacidosis 1. Always include basal insulin.
For Mild Hyperglycemia or Fasting Patients
Consider a basal-plus approach (0.1-0.25 U/kg/day basal insulin plus correctional doses before meals or every 6 hours if NPO) 1. This reduces hypoglycemia risk in patients with blood glucose <200 mg/dL, decreased oral intake, or perioperative status 1.
For Patients Without Diabetes or Well-Controlled on Oral Agents
Start with sliding scale insulin alone, but add basal insulin if unable to maintain glucose <180 mg/dL 1.
Critical Pitfalls to Avoid
Premixed insulin (70/30): Do not use in hospital settings - unacceptably high hypoglycemia rates 1.
Hypoglycemia risk: Basal-bolus regimens carry 4-6 times higher hypoglycemia risk than sliding scale alone 1. However, the superior glycemic control and reduced complications justify this risk when properly monitored. The incidence of mild hypoglycemia ranges 12-30% in controlled settings but may be higher in real-world practice 1.
Insulin Selection
Prefer long-acting basal analogs (glargine, detemir) over NPH for more physiologic profiles and lower hypoglycemia risk 6. Use rapid-acting analogs (aspart, lispro, glulisine) for prandial and correction doses 2, 6.
Intensification Strategy
If A1C remains above goal on basal insulin, add GLP-1 RA or dual GIP/GLP-1 RA before intensifying to full basal-bolus 2. This may reduce hypoglycemia and weight gain associated with insulin intensification.
Special Populations
TPN patients: Add regular human insulin directly to TPN solution 7.
Corticosteroid-induced hyperglycemia: Use NPH insulin, potentially dosed in morning to match steroid timing 2, 7.
Monitoring and Titration
Adjust insulin doses every 2-3 days based on glucose patterns 8. For hypoglycemia without clear cause, reduce corresponding insulin component by 10-20% 2. Assess for overbasalization signals: elevated bedtime-to-morning differential, postprandial excursions, or recurrent hypoglycemia 2.
The evidence strongly favors structured insulin regimens over reactive sliding scale approaches, with the most recent guidelines 1, 2 emphasizing individualized dosing based on patient risk factors while maintaining aggressive glycemic targets to reduce morbidity and mortality.